Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, hosted an official opening ceremony at its new UK headquarters on Milton Park Oxfordshire . Over 400 people, including employees and senior representatives from the regional and national business, academic, government and investor communities, celebrated the official opening of the flagship facility. Professor Sir John Bell GBE, FRS, Regius Professor of Medicine at the University of Oxford, wunveiled a commemorative plaque.
Adaptimmune’s state-of-the-art 67,000 square foot building comprises laboratory and office space accommodates all the Company’s UK research and development operations and corporate teams. The facility complements Adaptimmune’s newly built U.S. headquarters and clinical and manufacturing operations in Philadelphia, USA.
James Noble, Chief Executive Officer of Adaptimmune, said: “We started up Adaptimmune with three people in a small laboratory on Milton Park in 2008 to conduct research into engineered T-cell receptors to fight cancer, we now have more than 350 staff working out of our UK and U.S. facilities. Their substantial scientific, development and corporate expertise is focused on progressing our preclinical programs and accelerating the development of our wholly-owned pipeline with a common objective to bring breakthrough therapies to cancer patients.”